MARS1
Full Name
MARS1
Function
Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:11714285).
Plays a role in the synthesis of ribosomal RNA in the nucleolus (PubMed:10791971).
Plays a role in the synthesis of ribosomal RNA in the nucleolus (PubMed:10791971).
Biological Process
Cellular response to epidermal growth factor stimulus Source: CAFA
Cellular response to insulin stimulus Source: CAFA
Cellular response to platelet-derived growth factor stimulus Source: CAFA
Cellular response to starvation Source: CAFA
Methionyl-tRNA aminoacylation Source: UniProtKB
Positive regulation of transcription of nucleolar large rRNA by RNA polymerase I Source: CAFA
rRNA transcription Source: CAFA
tRNA aminoacylation for protein translation Source: GO_Central
Cellular response to insulin stimulus Source: CAFA
Cellular response to platelet-derived growth factor stimulus Source: CAFA
Cellular response to starvation Source: CAFA
Methionyl-tRNA aminoacylation Source: UniProtKB
Positive regulation of transcription of nucleolar large rRNA by RNA polymerase I Source: CAFA
rRNA transcription Source: CAFA
tRNA aminoacylation for protein translation Source: GO_Central
Cellular Location
Cytoplasm and Cytosol
Nucleus
Nucleolus
Note: Localizes to the nucleolus in proliferative cells but disappears in quiescent cells.
Nucleus
Nucleolus
Note: Localizes to the nucleolus in proliferative cells but disappears in quiescent cells.
Involvement in disease
Interstitial lung and liver disease (ILLD):
An autosomal recessive, life-threatening disorder characterized by respiratory insufficiency and progressive liver disease with onset in infancy or early childhood. Clinical features include failure to thrive, hypotonia, intermittent lactic acidosis, aminoaciduria, hypothyroidism, interstitial lung disease, pulmonary alveolar proteinosis, anemia, and liver canalicular cholestasis, steatosis, and iron deposition.
Charcot-Marie-Tooth disease 2U (CMT2U):
An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2U is a slowly progressive, autosomal dominant form characterized by late-adult onset.
An autosomal recessive, life-threatening disorder characterized by respiratory insufficiency and progressive liver disease with onset in infancy or early childhood. Clinical features include failure to thrive, hypotonia, intermittent lactic acidosis, aminoaciduria, hypothyroidism, interstitial lung disease, pulmonary alveolar proteinosis, anemia, and liver canalicular cholestasis, steatosis, and iron deposition.
Charcot-Marie-Tooth disease 2U (CMT2U):
An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2U is a slowly progressive, autosomal dominant form characterized by late-adult onset.
View more
Anti-MARS1 antibodies
+ Filters
Loading...
Target: MARS1
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: CBFYM-1730
Application*: DB, F, IC, IF, IP, WB
Target: MARS1
Host: Mouse
Antibody Isotype: IgG1, κ
Specificity: Human
Clone: 5G5
Application*: WB, E
Target: MARS1
Host: Mouse
Antibody Isotype: IgG1
Specificity: Mouse, Rat, Human
Clone: CBFYM-1732
Application*: WB, IP, F, IF
Target: MARS1
Host: Mouse
Specificity: Human, Mouse, Rat
Clone: CBFYM-1731
Application*: F, IC, IP, WB
Target: MARS1
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: CBFYM-1729
Application*: F, IC, IP, WB
Target: MARS1
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: CBFYM-0507
Application*: E, IC, WB
More Infomation
Hot products 
-
Mouse Anti-BCL2L1 Recombinant Antibody (H5) (CBMAB-1025CQ)
-
Mouse Anti-DES Monoclonal Antibody (440) (CBMAB-AP1857LY)
-
Mouse Anti-ENO2 Recombinant Antibody (H14) (CBMAB-E1341-FY)
-
Mouse Anti-AOC3 Recombinant Antibody (CBYY-0014) (CBMAB-0014-YY)
-
Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)
-
Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811) (CBMAB-C0866-FY)
-
Mouse Anti-ATP5F1A Recombinant Antibody (51) (CBMAB-A4043-YC)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-ACTG1 Recombinant Antibody (V2-179597) (CBMAB-A0916-YC)
-
Mouse Anti-BRCA2 Recombinant Antibody (CBYY-0790) (CBMAB-0793-YY)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-ALDOA Recombinant Antibody (A2) (CBMAB-A2316-YC)
-
Armenian hamster Anti-CD40 Recombinant Antibody (HM40-3) (CBMAB-C10365-LY)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Mouse Anti-ARHGDIA Recombinant Antibody (CBCNA-009) (CBMAB-R0415-CN)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




